This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson’s Disease (PD) who are on stable symptomatic PD medication.

You may be eligible if the following apply:
• Diagnosis of PD plus one of the other cardinal signs of PD (resting tremor, rigidity), without any other known or suspected cause of parkinsonism
• On symptomatic PD medication for at least 6 months
• A diagnosis of PD for at least 6 months to maximum 3 years at screening

Contact information

Name: Justine Reaume
Phone: 416-386-9761 extension 364

Share this: